Moderna Stock Reached New 52-Week High: What's Happening?

Moderna Inc. (NASDAQ: MRNA) shares reached a new 52-week high of approximately $198, surpassing the previous peak of $195.71, driven by positive anticipation surrounding upcoming clinical trial data for its experimental cancer treatment, intismeran autogene. The stock rose nearly 7% on Thursday after regulators accepted three research abstracts for presentation at the European Society for Medical Oncology Congress. Despite the rally, Bernstein analyst Courtney Breen maintained a Market Perform rating with a price target of $45, indicating skepticism about the stock's valuation relative to its current trading price.